Securing a FRAND licence with the world’s fifth largest handset maker could be a shot in the arm for the Swedish company, which has struggled to get royalties out of Chinese firms like Xiaomi and TCL
Supported by a healthy balance sheet, Marc Booth says the firm plans on a higher volume of smaller deals with three new areas identified for future growth
Congressional action is the only way to solve the uncertainty on section 101 of the US patent statute, argues Aaric Eisenstein of Personalised Media Communications
In a Delaware case Boehringer Ingelheim accuses the Illinois company of improper conduct in deliberately constructing a patent thicket to protect against generic versions of its blockbuster drug.
With new guidelines set to reshape patent examination, the USPTO head makes the case for revisiting subject matter precedent
The company behind Tik Tok bought out much of a struggling smartphone maker’s patent portfolio in January. USPTO assignments from last week show what assets Beijing-based ByteDance came away with
Senior decision makers from a wide range of companies are already confirmed to attend as demand for tickets exceeds the rate for last year's sell-out event in San Francisco
The settlement deal ends litigation by the Singapore company’s ZiiLabs unit against Nvidia, and will net shareholders around $17.5 million
The iPhone maker moves for declaratory judgment claiming non infringement of grants relating to charging technology
Record-breaking Celgene purchase, two decisions on the on-sale bar, Europe moves towards SPC manufacturing waiver, China proposes five-year patent term extension and much more
Coherus launched Delaware action against Amgen in what is likely to become an increasingly familiar life sciences litigation scenario.
PTAB reforms help fuel a miraculous rise up the latest International IP Index, but a recent Federal Circuit decision on eligibility highlights the serious challenges that remain - especially for life sciences companies
If the Commission and Apple are successful in rewriting the rules for chipmaker's licensing arm beware of unintended consequences that reduce choice and harm consumers, expert analyst states
The newest members of IAM's IP Asia Elite give us the inside scoop on what makes a great IP function tick
The Federal Circuit’s precedential judgment in Supernus Pharmaceuticals v Iancu is good news for rights holders – especially those in life sciences